TY - JOUR
T1 - Multi-platform assessment of transcriptional profiling technologies utilizing a precise probe mapping methodology
AU - Yu, Jinsheng
AU - Cliften, Paul F.
AU - Juehne, Twyla I.
AU - Sinnwell, Toni M.
AU - Sawyer, Chris S.
AU - Sharma, Mala
AU - Lutz, Andrew
AU - Tycksen, Eric
AU - Johnson, Mark R.
AU - Minton, Matthew R.
AU - Klotz, Elliott T.
AU - Schriefer, Andrew E.
AU - Yang, Wei
AU - Heinz, Michael E.
AU - Crosby, Seth D.
AU - Head, Richard D.
N1 - Publisher Copyright:
© 2015 Yu et al.
PY - 2015/9/18
Y1 - 2015/9/18
N2 - Background: The arrival of RNA-seq as a high-throughput method competitive to the established microarray technologies has necessarily driven a need for comparative evaluation. To date, cross-platform comparisons of these technologies have been relatively few in number of platforms analyzed and were typically gene name annotation oriented. Here, we present a more extensive and yet precise assessment to elucidate differences and similarities in performance of numerous aspects including dynamic range, fidelity of raw signal and fold-change with sample titration, and concordance with qRT-PCR (TaqMan). To ensure that these results were not confounded by incompatible comparisons, we introduce the concept of probe mapping directed "transcript pattern". A transcript pattern identifies probe(set)s across platforms that target a common set of transcripts for a specific gene. Thus, three levels of data were examined: entire data sets, data derived from a subset of 15,442 RefSeq genes common across platforms, and data derived from the transcript pattern defined subset of 7,034 RefSeq genes. Results: In general, there were substantial core similarities between all 6 platforms evaluated; but, to varying degrees, the two RNA-seq protocols outperformed three of the four microarray platforms in most categories. Notably, a fourth microarray platform, Agilent with a modified protocol, was comparable, or marginally superior, to the RNA-seq protocols within these same assessments, especially in regards to fold-change evaluation. Furthermore, these 3 platforms (Agilent and two RNA-seq methods) demonstrated over 80% fold-change concordance with the gold standard qRT-PCR (TaqMan). Conclusions: This study suggests that microarrays can perform on nearly equal footing with RNA-seq, in certain key features, specifically when the dynamic range is comparable. Furthermore, the concept of a transcript pattern has been introduced that may minimize potential confounding factors of multi-platform comparison and may be useful for similar evaluations.
AB - Background: The arrival of RNA-seq as a high-throughput method competitive to the established microarray technologies has necessarily driven a need for comparative evaluation. To date, cross-platform comparisons of these technologies have been relatively few in number of platforms analyzed and were typically gene name annotation oriented. Here, we present a more extensive and yet precise assessment to elucidate differences and similarities in performance of numerous aspects including dynamic range, fidelity of raw signal and fold-change with sample titration, and concordance with qRT-PCR (TaqMan). To ensure that these results were not confounded by incompatible comparisons, we introduce the concept of probe mapping directed "transcript pattern". A transcript pattern identifies probe(set)s across platforms that target a common set of transcripts for a specific gene. Thus, three levels of data were examined: entire data sets, data derived from a subset of 15,442 RefSeq genes common across platforms, and data derived from the transcript pattern defined subset of 7,034 RefSeq genes. Results: In general, there were substantial core similarities between all 6 platforms evaluated; but, to varying degrees, the two RNA-seq protocols outperformed three of the four microarray platforms in most categories. Notably, a fourth microarray platform, Agilent with a modified protocol, was comparable, or marginally superior, to the RNA-seq protocols within these same assessments, especially in regards to fold-change evaluation. Furthermore, these 3 platforms (Agilent and two RNA-seq methods) demonstrated over 80% fold-change concordance with the gold standard qRT-PCR (TaqMan). Conclusions: This study suggests that microarrays can perform on nearly equal footing with RNA-seq, in certain key features, specifically when the dynamic range is comparable. Furthermore, the concept of a transcript pattern has been introduced that may minimize potential confounding factors of multi-platform comparison and may be useful for similar evaluations.
KW - Fold-change
KW - Microarray
KW - RNA-seq
KW - TaqMan assay
KW - Transcript pattern
UR - http://www.scopus.com/inward/record.url?scp=84961166046&partnerID=8YFLogxK
U2 - 10.1186/s12864-015-1913-6
DO - 10.1186/s12864-015-1913-6
M3 - Article
C2 - 26385698
AN - SCOPUS:84961166046
SN - 1471-2164
VL - 16
JO - BMC genomics
JF - BMC genomics
IS - 1
M1 - 710
ER -